Results 11 to 20 of about 50,426 (246)

Hepatitis C Treatment and Alopecia Totalis [PDF]

Journal of Investigative Dermatology Symposium Proceedings, 2013
Peg-interferon alpha-2a and 2b and ribavirin have become the mainstays of chronic hepatitis C treatment. Although various cutaneous side effects have been reported, alopecia areata in its various forms have rare reports and has not been well categorized.
Carolyn Goh
openaire   +3 more sources

Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis [PDF]

Skin research and technology, 2023
Dear Editor, Alopecia totalis (AT) is a severe form of alopecia areata (AA) that affects the entire scalp. AA treatment depends on patient age, disease phase, and disease severity, and AT usually requires aggressive systemic treatment.1 For treatment of ...
Young Gue Koh, H. S. Han, J. Seok, Sun Young Choi, Kapsok Li, B. Kim, K. Yoo   +6 more
semanticscholar   +2 more sources

P56 Azathioprine-induced alopecia totalis and knuckle hyperpigmentation in a child with uveitis: test before you leap! [PDF]

Rheumatology Advances in Practice
Introduction Azathioprine is a common disease-modifying anti-rheumatic drug used in non-infectious uveitis. Although unusual, it has been associated with myelosuppression in genetically predisposed individuals who exhibit mutations in thiopurine S ...
P. Barman, Sabia Handa, A. K. Jindal, Reema Bansal   +3 more
semanticscholar   +2 more sources

Alopecia totalis successfully treated with modified platelet-rich plasma therapy in a patient recalcitrant to traditional treatment modalities

Clinical Dermatology Review, 2021
Alopecia areata (AA) is an autoimmune, nonscarring, inflammatory disorder of the scalp and/or body resulting in hair loss. Extensive AA such as alopecia totalis is increasingly unresponsive to conventional treatment modalities.
Sumit Gupta, Priyanka Borde Bisht, Charisma Kannan   +2 more
doaj   +2 more sources

Scalp micro-needling: A new tool in the treatment of alopecia totalis

Clinical Dermatology Review, 2020
Alopecia areata is the most common form of nonscarring alopecia. It may vary from a single round patch to that involving large surface area termed as alopecia totalis (AT).
Savitha L Beergouder, Apoorva Reshme
doaj   +2 more sources

Case Report: A novel KRT74 variant in an eight-year-old boy with alopecia totalis successfully treated with baricitinib

Frontiers in Medicine
Alopecia areata is an autoimmune condition characterized by non-scarring hair loss, with genetic factors playing a significant role in disease susceptibility.
Yidong Tan, Yidong Tan, Jinxiang Yang, Jinxiang Yang, Xuanyi Chen, Xuanyi Chen, Yihang Shen, Yihang Shen, Zhe Wu, Zhe Wu, Weinan Zhou, Weinan Zhou, Zhirong Yao, Zhirong Yao, Jingjun Zhao, Jingjun Zhao, Jianying Liang, Jianying Liang   +17 more
doaj   +2 more sources

A patient with rickets and alopecia totalis

The Journal of Clinical and Scientific Research, 2023
Rickets is a disorder of bone mineralisation. Common causes of rickets are dietary calcium and Vitamin deficiency. Mutations in vitamin D activity are known to cause Vitamin D-resistant rickets (VDRRs).
Shanthisree Edara, Sherin Philip, Vikram Halkurke Shivashankariah, Junaid Ahmed Jamadar, Vijaya Gowri Bandaru, C. V. Harinarayan   +5 more
semanticscholar   +2 more sources

A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis

Indian Dermatology Online Journal, 2023
Background: Alopecia areata (AA) presents with noncicatricial alopecia and has multifactorial etiology. Janus Kinase inhibitors (JAKibs) with potential efficacy and favorable side-effect profile are the first class of drugs to receive FDA approval in AA.
Savitha Sharath, K. Sardana, A. Khurana
semanticscholar   +2 more sources

Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis [PDF]

Journal of dermatology (Print)
This post‐hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) evaluated the efficacy and safety of ritlecitinib, an oral Janus kinase 3/TEC family kinase inhibitor, in patients with alopecia totalis (AT) and alopecia universalis (AU).
N. Mesinkovska, B. King, Xingqi Zhang, E. Guttman‐Yassky, Nina Magnolo, R. Sinclair, M. Mizuashi, Jerry Shapiro, E. Peeva, A. Banerjee, Liza Takiya, L. Cox, D. Wajsbrot, U. Kerkmann, Ernest Law, R. Wolk, G. Schaefer   +16 more
semanticscholar   +3 more sources

Alopecia totalis [PDF]

, 2020
INSERM
openaire   +2 more sources